POPULARITY
28 episodes with suny upstate medical university
6 episodes with suny upstate medical university
![The [P]Rehab Audio Experience](https://ivyfm.s3.amazonaws.com/i320/876012.jpg)
2 episodes with suny upstate medical university
2 episodes with suny upstate medical university
2 episodes with suny upstate medical university
2 episodes with suny upstate medical university
2 episodes with suny upstate medical university
2 episodes with suny upstate medical university
2 episodes with suny upstate medical university
Today, Dr. Andy Cutler interviews Dr. Katharine Phillips about identifying and treating body dysmorphic disorder (BDD). Join the discussion as they talk about how BDD presents, the treatments available for this debilitating disorder, and how clinicians can help their patients reach remission. Katharine Phillips, MD is a renowned psychiatrist and leading authority on body dysmorphic disorder (BDD). She serves as Professor of Psychiatry and DeWitt Wallace Senior Scholar at Weill Cornell Medical College and is an attending psychiatrist at New York-Presbyterian Hospital. Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York. Resources BDD Treatment Manuals International OCD Foundation - BDD Never miss an episode!
In this episode, Dr. Andy Cutler is joined by Dr. Jennifer Payne to discuss management of mood disorders influenced by fluctuations in reproductive hormones, particularly in women. They explore medication management during the perinatal period, emphasizing the risks associated with inadequately treated mood disorders. The conversation also addresses strategies for managing hormone-related mood disorders across reproductive stages, including premenstrual dysphoric disorder, premenstrual exacerbation, and perimenopausal depression. Jennifer L. Payne, MD is a psychiatrist specializing in reproductive psychiatry and mood disorders in women. She serves as Vice Chair of Research and Professor in the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia, directing the Reproductive Psychiatry Research Program. Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.
Join Dr. Andy Cutler and Dr. Cynthia Bulik as they discuss the challenges of diagnosing and treating binge eating disorder (BED). They explore the genetics, neurobiology, and clinical course of BED that inform treatment decisions, and examine how advances in genetic research and emerging pharmacological options may improve outcomes for individuals with BED. Cynthia Bulik, PhD, FAED is a Distinguished Professor of Eating Disorders in the Department of Psychiatry, a Professor of Nutrition in the Gillings School of Global Public Health and the Founding Director of the Center of Excellence for Eating Disorders at the University of North Carolina at Chapel Hill. Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York. Resources Eating Disorders Genetics Initiative (EDGI) 2 - edgi2.org National Eating Disorders Association - nationaleatingdisorders.org Families Empowered and Supporting the Treatment of Eating Disorders (FEAST) - feast-ed.org
Join Dr. Andy Cutler and Dr. Carla Sharp as they discuss the current conceptualization of borderline personality disorder (BPD), including diagnostic challenges, evidence-based treatments, and strategies to reduce stigma by framing BPD as a treatable condition. The conversation also covers recent updates to the APA's BPD guidelines. Carla Sharp, PhD is a distinguished clinical psychologist specializing in developmental psychopathology, particularly borderline personality disorder (BPD). She is a professor in the Clinical Psychology Doctoral Program and serves as the Associate Dean for Faculty and Research at the University of Houston. Additionally, she directs both the Adolescent Diagnosis, Assessment, Prevention, and Treatment Center and the Developmental Psychopathology Lab at the university. Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.
Our first ever repeat guest is Rachel Fabi, PhD, Associate Professor of Bioethics and Humanities at SUNY Upstate Medical University. She is a Faculty Research Affiliate at the Syracuse University Lerner Center for Public Health Promotion. She received her Ph.D. in Health Policy and Management, in the Bioethics and Health Policy track, at the Johns Hopkins Bloomberg School of Public Health, and served as the 2019-2021 National Academy of Medicine Greenwall Fellow in Bioethics. Dr. Fabi had previously joined us in September of 2023, on Season 5 Episode 2 of Bioethics in the Margins. She joins again today to discuss the timely topic of the effect of recent Executive Orders rescinding the 2021 guidance designating schools, churches and healthcare institutions as "safe zones" exempt from immigration enforcement. Dr. Fabi outlines specific strategies that institutions can adopt to protect students and patients, particularly designating areas clearly as private spaces, which require a judicial warrant for ICE agents to enter. She highlights the importance of proactive planning on the part of institutions. Kirk, Amelia and Dr. Fabi reflect on our moral obligations towards immigrants as a society and the specific obligations of ethicists in practice and discuss the importance of immigrant communities to the fabric of our society. Several resources that were mentioned in the episode are linked below:1. Toolkit for healthcare institutions curated by Mark Kuczewski2. Link to “red cards” to inform people of their rights3. Immigration Policy Tracking Project4. The Health of Newcomers by Patricia Illingworth and Wendy E. Parmet
Join Dr. Andy Cutler as he speaks with Dr. Anita Clayton about one of the most common yet least discussed side effects of psychotropic medications—sexual dysfunction. They explore the different aspects of sexual dysfunction that may arise as a side effect, how to distinguish these from symptoms of psychiatric or medical disorders, and how to collaborate with patients to effectively address this challenging issue. Anita H. Clayton, MD, Wilford W. Spradlin Professor and Chair of Psychiatry & Neurobehavioral Sciences, and Professor of Clinical Obstetrics & Gynecology at the University of Virginia School of Medicine, has focused her research on major depressive disorder, mood disorders associated with reproductive-life events in women (reproductive psychiatry), sexual dysfunction related to illness and medications, and the assessment and treatment of primary sexual disorders. Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York. Resources Changes in Sexual Functioning Questionnaire short- form (CSFQ-14) Validation study for CSFQ-14
In this podcast episode, Corey Zeigler, CIO of Helio Health, and Dr. Ross W. Sullivan from SUNY Upstate Medical University discuss an innovative program tackling opioid use disorder (OUD). The episode covers the implementation of a universal screening protocol, the success of the two-item conjoint screen (TICS) method, and the impact of the Bridge Clinic initiative. Dr. Sullivan shares insights on overcoming challenges and achieving improved patient outcomes, including reduced emergency department visits. Discover how healthcare IT is playing a crucial role in transforming addiction treatment and addressing the opioid crisis.What You'll Learn:Introduction to SUNY Upstate's Comprehensive Program: Gain insights into a holistic approach combining universal screening protocols and dedicated clinics to address opioid use disorder (OUD).Effective Screening Methods: Understand the implementation and efficacy of the two-item conjoint screen (TICS) method for identifying OUD across diverse healthcare settings like outpatient and emergency departments.Implementation Challenges and Solutions: Learn about the obstacles encountered while rolling out a universal screening protocol in a large healthcare system and strategies for overcoming them.Impactful Results: Discover the tangible outcomes of the program, such as reduced length of inpatient stays and a significant decrease in opioid-related ED visits.Collaborative Care Model: Explore how dedicated OUD teams collaborate with existing patient care teams and social workers to enhance treatment and post-hospitalization care.Sustainability and Future Expansions: Get acquainted with the plans for maintaining and expanding successful initiatives like the Bridge Clinic and TICS screening protocol.MODERATOR: Corey ZeiglerCIO, Helio Health Bio: Corey has been with Helio Health for about 5 years. They are a large substance use and behavioral health organization with 70 different locations throughout Central New York spanning from Albany in the eastern side to Rochester on the western side, down to the Pennsylvania border to the south and almost to Canada in the North. Their services include inpatient, outpatient, residential, affordable housing, homelessness and a lot of the health and human services functions in New York State. GUEST: Ross W. Sullivan, MD, FASAM Executive Medical Director, Helio Health Assistant Assistant Professor, Emergency Medicine, Toxicology, Addiction Medicine, SUNY Upstate Medical UniversityBio: Dr. Sullivan is the Executive Medical Director at Helio Health in Central New York and a recognized expert in addiction medicine. He completed his medical education, residency in Emergency Medicine, and toxicology fellowship at SUNY Upstate Medical University. Dr. Sullivan also serves as a faculty member in Emergency Medicine and directs the Medical Toxicology fellowship at SUNY Upstate. He has co-authored several publications on overdose and addiction and contributes his expertise to various advisory panels and workgroups, including NY-OASAS and the NY-DOH buprenorphine work group. Additionally, he is the Treasurer and Board Member of the New York Society of Addiction Medicine (NYSAM).
In the second episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we're speaking with Dr. Erin Crane who will highlight how HRD testing provides helpful information to ovarian cancer patients. Erin K. Crane, MD, MPH, is a gynecologic oncologist with Atrium Health Levine Cancer in Charlotte, North Carolina. A graduate of the SUNY Upstate Medical University in Syracuse, NY, Dr. Crane completed her residency at the University of Virginia and a fellowship at The University of Texas MD Anderson Cancer Center in Gynecologic Oncology. She is board certified by the American Board of Obstetrics and Gynecology in Gynecologic Oncology and Obstetrics and Gynecology. Dr. Crane is a Clinical Associate Professor of Obstetrics and Gynecology at the Wake Forest University School of Medicine. For more information, visit https://www.azprecisionmed.com/tumor-type/ovarian-cancer/hrd-testing.html For patient resources, please visit TestForHRD.com. This podcast does not necessarily reflect the opinions of AstraZeneca and are the spokesperson's opinions and experience.
Join Dr. Andy Cutler as he speaks with Dr. Christine Moutier about the unintended effects of the FDA boxed warnings on antidepressant use in pediatric patients—specifically, the underdiagnosis and undertreatment of depression. Their conversation highlights the importance of effectively treating depression to reduce suicide across the lifespan. Christine Yu Moutier, MD is a leading psychiatrist and the Chief Medical Officer at the American Foundation for Suicide Prevention (AFSP). Since joining AFSP in 2013, Dr. Moutier has led a nationwide movement combining scientific research and grassroots efforts to reduce suicide rates. She has testified before Congress, presented at the White House, and frequently contributes to major media outlets on mental health issues. Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York. Resources American Foundation for Suicide Prevention - https://afsp.org/ Save $100 on registration for 2025 NEI Spring Congress with code NEIPOD25 Register today at nei.global/spcongress25f Never miss an episode!
In the second episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we’re speaking with Dr. Erin Crane who will highlight how HRD testing provides helpful information to ovarian cancer patients. Erin K. Crane, MD, MPH, is a gynecologic oncologist with Atrium Health Levine Cancer in Charlotte, North Carolina. A graduate of the SUNY Upstate Medical University in Syracuse, NY, Dr. Crane completed her residency at the University of Virginia and a fellowship at The University of Texas MD Anderson Cancer Center in Gynecologic Oncology. She is board certified by the American Board of Obstetrics and Gynecology in Gynecologic Oncology and Obstetrics and Gynecology. Dr. Crane is a Clinical Associate Professor of Obstetrics and Gynecology at the Wake Forest University School of Medicine. For more information, visit https://www.azprecisionmed.com/tumor-type/ovarian-cancer/hrd-testing.html For patient resources, please visit TestForHRD.com. This podcast does not necessarily reflect the opinions of AstraZeneca and are the spokesperson's opinions and experience.
In the second episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we’re speaking with Dr. Erin Crane who will highlight how HRD testing provides helpful information to ovarian cancer patients. Erin K. Crane, MD, MPH, is a gynecologic oncologist with Atrium Health Levine Cancer in Charlotte, North Carolina. A graduate of the SUNY Upstate Medical University in Syracuse, NY, Dr. Crane completed her residency at the University of Virginia and a fellowship at The University of Texas MD Anderson Cancer Center in Gynecologic Oncology. She is board certified by the American Board of Obstetrics and Gynecology in Gynecologic Oncology and Obstetrics and Gynecology. Dr. Crane is a Clinical Associate Professor of Obstetrics and Gynecology at the Wake Forest University School of Medicine. For more information, visit https://www.azprecisionmed.com/tumor-type/ovarian-cancer/hrd-testing.html For patient resources, please visit TestForHRD.com. This podcast does not necessarily reflect the opinions of AstraZeneca and are the spokesperson's opinions and experience.
Join Dr. Andy Cutler as he talks with Dr. Jeffrey Strawn about how clinicians can determine the appropriate scenarios for benzodiazepine deprescribing, best practices for benzodiazepine tapering, and how to balance patient preferences to ensure best outcomes. Jeffrey R. Strawn, MD is a Professor and Associate Vice Chair of Research in the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati (UC) College of Medicine, the Assistant Director of Clinical and Translational Research in the Center for Clinical & Translational Science and Training at UC, and an Associate Professor in the Department of Pediatrics at UC and Cincinnati Children's Hospital Medical Center. Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York. Save $100 on registration for 2025 NEI Spring Congress with code NEIPOD25 Register today at nei.global/spcongress25p Never miss an episode!
In this episode, Dr. Robert Corona, CEO of SUNY Upstate Medical University, shares insights on the institution's growth, its strategic goals for 2025, and its efforts to enhance patient access and quality care. He discusses key initiatives, including the adoption of Lean Six Sigma principles and the expansion of access points in response to the region's increasing healthcare demands.
In this episode, Christopher Tanski, MD, MSEd - Associate Chief Medical Officer at SUNY Upstate Medical University, discusses the transformative potential of AI in clinical and operational settings, the promise of hospital-at-home programs, and the evolving landscape of healthcare delivery. He also shares his leadership goals for 2025, focusing on fostering efficiency and innovation in a dynamic healthcare environment.
To donate to my PayPal (thank you): https://paypal.me/danieru22?country.x=US&locale.x=en_US I apologize for any poor audio and no video. We had technical difficulties. I hope you enjoy the conversation, nonetheless. Dr Pies is Professor Emeritus of Psychiatry and Lecturer on Bioethics and Humanities, SUNY Upstate Medical University; Clinical Professor of Psychiatry, Tufts University School of Medicine; and Editor in Chief Emeritus of Psychiatric Times (2007-2010). Dr Pies is the author of several books. Amazon: https://www.amazon.com/stores/Ronald-W.-Pies/author/B001HCU3SY?ref=ap_rdr&isDramIntegrated=true&shoppingPortalEnabled=true&ccs_id=a7c6f7ea-8218-47ac-8e44-552060df69b4 Psychiatric Times: https://www.psychiatrictimes.com/authors/ronald-w-pies-md Note: Information contained in this video is for educational purposes only and is not intended as a substitute for treatment or consultation with a mental health professional or business consultant.
******Support the channel****** Patreon: https://www.patreon.com/thedissenter PayPal: paypal.me/thedissenter PayPal Subscription 5 Dollars: https://tinyurl.com/ycmr9gpz PayPal Subscription 10 Dollars: https://tinyurl.com/y9r3fc9m PayPal Subscription 20 Dollars: https://tinyurl.com/y95uvkao ******Follow me on****** Website: https://www.thedissenter.net/ The Dissenter Goodreads list: https://shorturl.at/7BMoB Facebook: https://www.facebook.com/thedissenteryt/ Twitter: https://x.com/TheDissenterYT This show is sponsored by Enlites, Learning & Development done differently. Check the website here: http://enlites.com/ Dr. L. Syd M. Johnson is a philosopher/bioethicist/neuroethicist, a Clinical Ethics Consultant, and Associate Professor of Bioethics and Humanities at SUNY Upstate Medical University. She is a member of the Neuroethics Working Group of the NIH BRAIN Initiative, Associate Editor for Neuroethics, and the co-founder of the American Society for Bioethics + Humanities Animal Bioethics Affinity Group. Her research focuses on ethical issues related to brain injuries, including sport-related neurotrauma, brain death, and disorders of consciousness. She is the author of Philosophical, Medical, and Legal Controversies About Brain Death. In this episode, we focus on Philosophical, Medical, and Legal Controversies About Brain Death. We tackle the concept of “death” from a medical and legal perspective, and how it is commonly understood. We explore how the concept of “brain death” evolved over time, the different types of brain death, brain-body dualism in medicine, and the metaphysical and moral commitments behind brain death. We go through epistemic, medical, and ethical challenges to brain death. We discuss what happens when there is conflict in worldviews between patients and doctors, and the value of patient autonomy. Finally, we talk about reasonable objections to the medical view of death. -- A HUGE THANK YOU TO MY PATRONS/SUPPORTERS: PER HELGE LARSEN, JERRY MULLER, BERNARDO SEIXAS, ADAM KESSEL, MATTHEW WHITINGBIRD, ARNAUD WOLFF, TIM HOLLOSY, HENRIK AHLENIUS, FILIP FORS CONNOLLY, ROBERT WINDHAGER, RUI INACIO, ZOOP, MARCO NEVES, COLIN HOLBROOK, PHIL KAVANAGH, SAMUEL ANDREEFF, FRANCIS FORDE, TIAGO NUNES, FERGAL CUSSEN, HAL HERZOG, NUNO MACHADO, JONATHAN LEIBRANT, JOÃO LINHARES, STANTON T, SAMUEL CORREA, ERIK HAINES, MARK SMITH, JOÃO EIRA, TOM HUMMEL, SARDUS FRANCE, DAVID SLOAN WILSON, YACILA DEZA-ARAUJO, ROMAIN ROCH, DIEGO LONDOÑO CORREA, YANICK PUNTER, CHARLOTTE BLEASE, NICOLE BARBARO, ADAM HUNT, PAWEL OSTASZEWSKI, NELLEKE BAK, GUY MADISON, GARY G HELLMANN, SAIMA AFZAL, ADRIAN JAEGGI, PAULO TOLENTINO, JOÃO BARBOSA, JULIAN PRICE, EDWARD HALL, HEDIN BRØNNER, DOUGLAS FRY, FRANCA BORTOLOTTI, GABRIEL PONS CORTÈS, URSULA LITZCKE, SCOTT, ZACHARY FISH, TIM DUFFY, SUNNY SMITH, JON WISMAN, WILLIAM BUCKNER, PAUL-GEORGE ARNAUD, LUKE GLOWACKI, GEORGIOS THEOPHANOUS, CHRIS WILLIAMSON, PETER WOLOSZYN, DAVID WILLIAMS, DIOGO COSTA, ALEX CHAU, AMAURI MARTÍNEZ, CORALIE CHEVALLIER, BANGALORE ATHEISTS, LARRY D. LEE JR., OLD HERRINGBONE, MICHAEL BAILEY, DAN SPERBER, ROBERT GRESSIS, IGOR N, JEFF MCMAHAN, JAKE ZUEHL, BARNABAS RADICS, MARK CAMPBELL, TOMAS DAUBNER, LUKE NISSEN, KIMBERLY JOHNSON, JESSICA NOWICKI, LINDA BRANDIN, GEORGE CHORIATIS, VALENTIN STEINMANN, PER KRAULIS, ALEXANDER HUBBARD, BR, MASOUD ALIMOHAMMADI, JONAS HERTNER, URSULA GOODENOUGH, DAVID PINSOF, SEAN NELSON, MIKE LAVIGNE, JOS KNECHT, LUCY, MANVIR SINGH, PETRA WEIMANN, CAROLA FEEST, MAURO JÚNIOR, 航 豊川, TONY BARRETT, BENJAMIN GELBART, NIKOLAI VISHNEVSKY, STEVEN GANGESTAD, AND TED FARRIS! A SPECIAL THANKS TO MY PRODUCERS, YZAR WEHBE, JIM FRANK, ŁUKASZ STAFINIAK, TOM VANEGDOM, BERNARD HUGUENEY, CURTIS DIXON, BENEDIKT MUELLER, THOMAS TRUMBLE, KATHRINE AND PATRICK TOBIN, JONCARLO MONTENEGRO, AL NICK ORTIZ, NICK GOLDEN, AND CHRISTINE GLASS! AND TO MY EXECUTIVE PRODUCERS, MATTHEW LAVENDER, SERGIU CODREANU, BOGDAN KANIVETS, ROSEY, AND GREGORY HASTINGS!
Hey Team! This week, we've got an incredible guest, Dr. Stephen Faraone, one of the world's foremost experts on ADHD. Let me just give you a quick rundown of just how influential Dr. Faraone is: He has authored over 700 journal articles, editorials, chapters, and books Listed as the eighth-highest producer of High Impact Papers in Psychiatry from 1990 to 1999 as determined by the Institute for Scientific Information (ISI). In 2005, the ISI listed him as the second-highest cited author in the area of ADHD. In 2019 and 2020, his citation metrics placed him in the top 0.01% of scientists across all fields. In 2002 he was inducted into the CHADD Hall of Fame Currently, Dr. Faraone serves as a distinguished professor of psychiatry, physiology, and neuroscience at SUNY Upstate Medical University and president of the World Federation of ADHD. So yeah, this guy knows what he's talking about when it comes to ADHD and if you only listen to one episode of the podcast this year, I'd suggest this one. One of the focal points in this conversation is the ADHD Evidence Project, which Dr. Faraone started to help fight misinformation about ADHD and give free access to the information we have about ADHD. On the site - which can be found at ADHDevidence.org - you can find the International Consensus Statement, which provides 208 statements strongly supported by ADHD research. In the episode we get more into what went into the process of making the statement and the standards of research. In the episode, we also discuss evidence-based treatments, debunk common myths, and discuss what really works when managing ADHD. If you'd life to follow along on the show notes page you can find that at HackingYourADHD.com/202 This Episode's Top Tips Stick to treatments that have been proven effective through rigorous studies. Large studies and meta-analyses are more reliable than small studies when determining ADHD treatments. Not all ADHD treatments you find online are helpful—be cautious of sources that aren't peer-reviewed. Beware of misinformation as well as misleading information that can lead you down the wrong treatment path. While some alternative treatments may help, their effects are often significantly smaller compared to standard stimulant medication. When thinking about approaching what we do to help manage our ADHD, we want to think about the magnitude of the effect and do the things that will help the most first.
BUFFALO, NY- October 16, 2024 – A new #review was #published in Oncotarget's Volume 15 on October 1, 2024, entitled, “Molecular chaperones: Guardians of tumor suppressor stability and function.” As highlighted in the abstract of this paper, "tumor suppressor" describes a diverse set of genes typically involved in suppressing metastasis, but which can lead to tumorigenesis when loss-of-function mutations occur. Despite the varied structures and functions of tumor suppressor proteins, many share a common regulatory mechanism—they are "clients" of molecular chaperones, and they rely on an intracellular network of chaperones and co-chaperones to maintain their stability. Mutations in tumor suppressors that disrupt proper chaperoning prevent cells from maintaining sufficient protein levels for normal physiological function. In their review, researchers Jennifer A. Heritz, Sarah J. Backe, and Mehdi Mollapour from SUNY Upstate Medical University and New York VA Health Care in Syracuse, New York, discuss the role of molecular chaperones Hsp70 and Hsp90 in maintaining the stability and functional integrity of tumor suppressors. They also detail the contributions of co-chaperones prefoldin, HOP, Aha1, p23, FNIP1/2, and Tsc1, as well as the chaperonin TRiC, to tumor suppressor stability. “Overall, it is clear that oncogenesis can result from the dysregulation of tumor suppressor stabilization by chaperones.” DOI - https://doi.org/10.18632/oncotarget.28653 Correspondence to - Mehdi Mollapour - mollapom@upstate.edu Video short - https://www.youtube.com/watch?v=V5OFjeqaH3A Sign up for free Altmetric alerts about this article: https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28653 Subscribe for free publication alerts from Oncotarget: https://www.oncotarget.com/subscribe/ Keywords - cancer, molecular chaperone, tumor suppressor, renal cell carcinoma, Birt-Hogg-Dubé (BHD) syndrome, TSC syndrome About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Andrew J. Cutler, MD Guest: Michelle Scargle, MD Tardive dyskinesia is quite common as up to 20 percent of patients may develop this hyperkinetic movement disorder. But despite its prevalence, there are many barriers that can keep us from screening patients for tardive dyskinesia. To learn more about these barriers and how we can overcome them to optimize our screening approach, Dr. Charles Turck speaks with Drs. Andrew Cutler and Michelle Scargle. Dr. Cutler is a Clinical Associate Professor in the Department of Psychiatry and Behavioral Sciences at the SUNY Upstate Medical University in Syracuse, New York, and Dr. Scargle is the Chief Psychiatrist at Concord Health in Clearwater, Florida.
Dr. Khanum, Dr. Aida or Dr. K as some patients call her has lived in Houston since 2003. She completed her residency in Pediatrics at SUNY Upstate Medical University in Syracuse, New York. She continued her training by completing a Fellowship in Academic General Pediatrics at Baylor College of Medicine. Simultaneously, she completed a Masters in Public Health from UT School of Public Health. She has practiced in the Greater Houston area as a Board-Certified Pediatrician since the completion of her training in 2003. Through her more than 20 years of experience, she has seen first-hand how parents juggle their personal and professional lives. She found a need for a pediatric clinic that was in an easily accessible location within one of the busiest hubs of Houston – the City of Bellaire. This need, along with her desire to establish a practice with a neighborhood feel, led to the creation of Pediatric Pod. Dr. Aida Khanum is a mother to 3 active young boys and lives with her husband and family in the City of Bellaire. She is involved in the local school and community. She speaks multiple languages including Spanish, German, Urdu and Hindi. She has travelled to various parts of the world – Southeast Asia, the Middle East, Africa, Europe and Central America – but is very proud to call Houston her home. Dr. Aida Khanum stands out with her experience, wealth of knowledge, and desire to provide the best loving care possible for her patients. Connect on Social Media Pediatricpod on all platforms
BUFFALO, NY- August 15, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on August 14, 2024, entitled, “A nanobody against the V-ATPase c subunit inhibits metastasis of 4T1-12B breast tumor cells to lung in mice.” The vacuolar H+-ATPase (V-ATPase) is an ATP-dependent proton pump that functions to control the pH of intracellular compartments as well as to transport protons across the plasma membrane of various cell types, including cancer cells. Researchers Zhen Li, Mohammed A. Alshagawi, Rebecca A. Oot, Mariam K. Alamoudi, Kevin Su, Wenhui Li, Michael P. Collins, Stephan Wilkens, and Michael Forgac from Tufts University School of Medicine; Tufts University; Dana Farber Cancer Institute, Harvard Medical School; University of Minnesota School of Medicine; Prince Sattam Bin Abdulaziz University; Korro Bio; SUNY Upstate Medical University; and Foghorn Therapeutics, have previously shown that selective inhibition of plasma membrane V-ATPases in breast tumor cells inhibits the invasion of these cells in vitro. They have now developed a nanobody directed against an extracellular epitope of the mouse V-ATPase c subunit. “We show that treatment of 4T1-12B mouse breast cancer cells with this nanobody inhibits V-ATPase-dependent acidification of the media and invasion of these cells in vitro.” The research team further found that injecting this nanobody into mice implanted with 4T1-12B cells orthotopically in the mammary fat pad inhibited the metastasis of tumor cells to the lungs. “In conclusion, our results indicate that a nanobody directed against an extracellular epitope expressed on the surface of the V-ATPase is able to inhibit activity of cell surface V-ATPases in 4T1-12B breast cancer cells, inhibit in vitro invasion of these cells and inhibit metastasis of these cells to lung following their implantation in the mammary fat pad of mice.” DOI - https://doi.org/10.18632/oncotarget.28638 Correspondence to - Michael Forgac - michael.forgac@tufts.edu Video short - https://www.youtube.com/watch?v=4eLGqvSfAgg Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28638 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, vacuolar ATPase, breast cancer, invasion, tumor metastasis, tumor growth About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
Elon Musk's project Neuralink has been bringing a concept that seems out of science fiction, brain implants that allow users to control tech, into reality. So far, the company has implanted the device into a subject with quadriplegia. While he was able to do things like play online chess, he then lost some of the ability when parts of the device slipped out of place. This all begs questions about safety, ethics and the future of the human relationship with technology. Our team at “Something Offbeat” reached out to two experts – L. Syd M. Johnson, associate professor of bioethics and humanities at SUNY Upstate Medical University, and science journalist Faye Flam – to dive into them.
Dr. Robert Gregory discusses his Dynamic Deconstructive Psychotherapy (DDP) and Psychiatry High Risk Program, an evidence based alternative to dialectical behaviour therapy for people with borderline personality disorder. He also shares his insights on a concept of "embedded badness", the neuroscience behind BPD, and the impacts of academia on promising new treatment options. Dr. Robert Gregory is a Professor of Psychiatry at SUNY Upstate Medical University. He is the developer of an evidence-based treatment for borderline personality disorder called Dynamic Deconstructive Psychotherapy and is the founder of the Psychiatry High Risk Program, a recovery-based suicide prevention program for adolescents and young adults that uses Dynamic Deconstructive Psychotherapy as its core treatment.To find out more about Dynamic Deconstructive Therapy including handouts click here.Send us a Text Message.Support the Show.You can find Laurie and Sara on Instagram to follow their day to day lives even further @laurieanned and @saraswellnessway. You can also find the podcast on IG @boldbeautifulborderline Leave us a voicemail about your thoughts on the show at boldbeautifulborderline.comRegister for our free peer support group at https://www.eventbrite.ca/e/the-super-feelers-club-tickets-145605434775Register for our low-barrier drop-in DBT group at https://www.thewellnesswayllc.comPurchase the Exploring Your Borderline Strengths Journal at https://www.amazon.com/Exploring-Your-Borderline-Strengths-Amundson/dp/B0C522Y7QT/ref=sr_1_1?crid=IGQBWJRE3CFX&keywords=exploring+your+borderline+strengths&qid=1685383771&sprefix=exploring+your+bor%2Caps%2C164&sr=8-1 If you like the show we would love if you could rate, subscribe and support us on Patreon. Patreon info here: https://www.patreon.com/boldbeautifulborderline?fan_landing=true ...
In this episode "ASTCT Talks,” hosts Rebecca Epperly, MD, and Aimee Talleur, MD, from St. Jude Children's Research Hospital, dive into the pioneering realm of CAR T-cell therapy and its late effects on pediatric patients. The discussion unfolds at the intersection of innovation and caution, highlighting the recent sessions from the 2024 Tandem meetings. They explore the emerging challenges and lack of data concerning long-term impacts of this revolutionary treatment, particularly in pediatric, adolescent, and young adult populations. This episode sheds light on both the immense potential and the imperative need for comprehensive studies to better understand and mitigate the long-term consequences of cellular therapies in treating high-risk malignancies. About Dr. Rebecca Epperly, MD Dr. Rebecca Epperly is an Instructor in the Department of Bone Marrow Transplantation and Cellular Therapy (BMTCT) at St. Jude Children's Research Hospital. After gaining undergraduate degrees in biochemistry (BS) and music performance (BA), she received an MD from the University of Iowa Carver College of Medicine. She then completed pediatrics residency at the UPMC Children's Hospital of Pittsburgh and fellowships in pediatric hematology/oncology and BMTCT at St. Jude. As a clinician scientist, she is now working to improve outcomes for pediatric patients with high-risk malignancies using cellular based immunotherapy, with a focus on developing early-phase CAR T cell studies and evaluating the delayed effects of novel therapies. About Dr. Aimee Talleur, MD Dr. Aimee Talleur is an Assistant Member in the Department of Bone Marrow Transplantation and Cellular Therapy (BMTCT) at St. Jude Children's Research Hospital, specializing in the clinical investigation of novel immunotherapies for the treatment of high-risk malignant disorders. She completed her BA at Union College, MD at SUNY Upstate Medical University, pediatric residency at Children's National Medical Center, and fellowships in pediatric hematology/oncology and BMTCT at St. Jude. As a clinician scientist, Dr. Talleur focuses on the advancement of novel cellular therapies through early-phase clinical trials, including CAR T cell therapy. Additionally, her work includes the evaluation of acute and long-term toxicities of this immunotherapy approaches, seeking to better define such toxicities to inform upon predictive and intervention strategies.
In this CME episode, Dr. Andrew Cutler interviews Dr. Jeffrey Strawn about the role of pharmacogenomic testing in guiding treatment of major depressive disorder (MDD). They discuss how pharmacogenomic testing works, the impact of failed treatments and side effects on patients with MDD, and the clinical applications and future directions of pharmacogenomic testing. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD23-GEN Learning Objectives: After completing this educational activity, you should be better able to: Recognize the role of a patient's genetics in informing the efficacy and tolerability of antidepressants Consider opportunities to use pharmacogenomics as an evidence-based tool that can be employed to inform clinical decision making Implement pharmacogenomic testing to optimize patient outcomes, including symptom improvement, medication response, and remission rate Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types: The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Associate: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora, Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma Interviewee Jeffrey R. Strawn, MD Professor, Department of Psychiatry and Behavioral Neuroscience and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH Grant/Research: Allergan/AbbVie Consultant/Advisor: Cerevel, Intra-Cellular, Otsuka Pre-Interview Author Gabriela Alarcón, PhD Senior Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee, Content Editor, and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Support: This activity is supported by an unrestricted educational grant from Myriad Genetics. Released: December 13, 2023 CME/CE credit expires: December 13, 2026
In this CME episode, Dr. Andrew Cutler interviews Dr. Vladimir Maletic about the impact of residual symptoms on patients with major depressive disorder, as well as treatment modifications to address residual symptoms in these individuals. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD23-MDD Learning Objectives: After completing this educational activity, you should be better able to: Describe the burden of residual symptoms in patients with major depressive disorder (MDD) Implement measurement-based care to assess residual MDD symptoms Modify treatment strategies to address residual MDD symptoms, including cognitive impairment, anhedonia, emotional blunting, and sexual dysfunction Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types: The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Associate: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora, Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma Interviewee Vladimir Maletic, MD, MS Clinical Professor, Department of Psychiatry and Behavioral Science, University of South Carolina School of Medicine Greenville, SC Consultant/ Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Biogen/Sage, Boehringer Ingelheim, Cervel, Intra-Cellular, Janssen, Jazz, Lundbeck, Neurelis, Neumora, Noven, Otsuka, Pax Medica, Relmada, Sunovion, Supernus, Takeda Speakers Bureau: AbbVie, Alfasigma, Alkermes, Axsome, Corium, Intracellular, Janssen, Lundbeck, Otsuka, Sunovion, Supernus, Takeda Pre-Interview Author Caroline L. O'Brien, MS Assistant Manager, Grant Development, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee, Content Editor, and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Support: This activity is supported by an unrestricted educational grant from Takeda. Released: November 29, 2023 CME/CE credit expires: November 29, 2026
We are joined by Rachel Fabi, PhD, Associate Professor of Bioethics and Humanities at SUNY Upstate Medical University. She is a Faculty Research Affiliate at the Syracuse University Lerner Center for Public Health Promotion. She received her Ph.D. in Health Policy and Management, in the Bioethics and Health Policy track, at the Johns Hopkins Bloomberg School of Public Health, and served as the 2019-2021 National Academy of Medicine Greenwall Fellow in Bioethics.Dr. Fabi shares her insights on policies that affect the health of immigrants and refugees in the United States, and discusses her research on a broad range of topics such as access to care, reproductive health and treatment in ICE detention. Listen to the end for her insights into the role of physician advocacy.
In this CME episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl and Dr. Sarah Vinson about the ethicality and morality of involuntary treatment for serious mental illness (SMI), the relationship between SMI and the criminal justice system, and community-based changes that are being pursued to improve treatment and reduce the criminalization of SMI. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD23-SMI Learning Objectives: After completing this educational activity, you should be better able to: Recognize the neuroethics involved in involuntary treatment of serious mental illness Identify methods to prevent patients with serious mental illness from entering the criminal justice system, including the utility of diversion programs Institute community-based changes that have the potential to reduce the criminalization of serious mental illness, both on the individual and the policy level Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity does not pertain to pharmacology and is worth 0.0 continuing education hour of pharmacotherapeutics. Credit Types: The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Associate: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits™ Interprofessional Continuing Education: IPCE credit for learning and change Peer Review: The content was peer-reviewed by an MD specializing in forensic psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora, Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma Interviewees Stephen M. Stahl, MD, PhD, DSc (Hon.) Clinical Professor, Department of Psychiatry and Neuroscience, University of California, Riverside School of Medicine, Riverside, CA Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Honorary Visiting Senior Fellow, University of Cambridge, Cambridge, UK Editor-in-Chief, CNS Spectrums Director of Psychopharmacology Services, California Department of State Hospitals Grant/Research: Acadia, Alkermes, Allergan/AbbVie, Arbor, AssureX, AstraZeneca, Avanir, Axovant, Biogen, Boehringer Ingelheim Braeburn, BristolMyer Squibb, Celgene, CeNeRex, Cephalon, Daiichi Sankyo-Brazil, Dey, Eisai, Forest, Genomind, Glaxo Smith Kline, Harmony Biosciences, Indivior, Intra-Cellular, Ironshore, Janssen, JayMac, Jazz, Lilly, Lundbeck, Merck, Neurocrine, Neuronetics, Novartis, Otsuka, Pear, Pfizer, Reviva, Roche, Sage, Servier, Shire, Sprout, Sunovion, Supernus, Takeda, Teva, Tonix, Torrent, Vanda Consultant/Advisor: Acadia, Adamas, Alkermes, Allergan/AbbVie, Altus, Arbor, AstraZeneca, Avanir, Axovant, Axsome, Biogen, Biomarin, Biopharma, Celgene, Cerevel, ClearView, Clexio, Concert, DepotMed, Done, EMD Serono, Eisai, Enveric, Eurolink, Fabre-Kramer, Ferring, Forest, Gedeon Richter, Genetica, Genomind, Innovative Science Solutions, Impel, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Libbs, Lilly, Lipidio, Longboard, Lundbeck, Merck, Neos, NeuraWell, Neurocrine, NeuroPharma, Novartis, Noveida, Otsuka, Perrigo, Pfizer, Pierre Fabre, Proxymm, Recordati, Relmada, Reviva, Sage, Saniona, Servier, Shire, Sprout, Sunovion, Supernus, Takeda, Taliaz, Teva, Tonix, Tris, Trius, Vanda, Vertex, Viforpharma Speakers Bureau: Acadia, Allergan/AbbVie, Genentech, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Servier, Sunovion, Takeda, Teva Options Holdings: Delix, Genomind, Lipidio, NeuraWell Sarah Y. Vinson, MD, FAPA Interim Department Chair; Clinical Associate Professor; Director, Child and Adolescent Psychiatry Fellowship Program; Department of Psychiatry and Behavioral Sciences, Morehouse School of Medicine, Atlanta, GA Medical Director, Substance Abuse and Mental Health Services Administration (SAMHSA) African American Behavioral Health Center of Excellence, Atlanta, GA No financial relationships to disclose. Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Senior Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee, Content Editor, and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Support: This activity is supported by an unrestricted educational grant from Alkermes. Released: July 25, 2023 CME/CE credit expires: July 24, 2026
Christopher Gaiteri, Ph.D., is Associate Professor of Psychiatry & Behavioral Sciences and Empire Innovation Scholar at SUNY Upstate Medical University. Dr. Gaiteri earned his undergraduate degree from Washington & Lee University and his doctorate from the University of Pittsburgh. He joined Rush University as assistant professor of neurological sciences and computational neuroscientist after serving as Research Scientist at the Allen Institute for Brain Science and Senior Scientist at Sage Bionetworks. In today's podcast, Dr. Gaiteri responds to the following questions: 1. What were the origins to your approach and how does it differ from the more traditional way of framing research about the onset and development of Alzheimer's disease? 2. Statistical techniques such as factor analysis and canonical correlation were used in research to take a large number of measures of variables and allow those statistical techniques to sort out which of those variables covaried and which patterns emerged that could suggest relationships to be looked at more closely. In your approach using "big data" do you have a particular notion of which variables you select ought to covary? In other words, do you have a "pre-theory" that guides your selection of variables? 3. Alzheimer's is nearly always associated with the aging process, perhaps implicitly arguing that the aging process alone is a causal agent for the onset and progression of the disease. More recently and not without some controversy, some researchers have suggested that aging itself should be considered a disease. From your perspective, does the question of age influence your view on how to go about framing analyses of data bearing on the inception and development of Alzheimer's? 4. In your career to date, how has the leadership of organizations in which you have worked influenced you and your research? Are there characteristics of persons who hold leadership roles that you single out as especially important to your work? INNOVATORS is a podcast production of Harris Search Associates. *The views and opinions shared by the guests on INNOVATORS do not necessarily reflect the views of the interviewee's institution or organization.*
A new review paper was published in Oncotarget's Volume 14 on April 26, 2023, entitled, “Systemic AL amyloidosis: current approach and future direction.” In this review, researchers Maroun Bou Zerdan, Lewis Nasr, Farhan Khalid, Sabine Allam, Youssef Bouferraa, Saba Batool, Muhammad Tayyeb, Shubham Adroja, Mahinbanu Mammadii, Faiz Anwer, Shahzad Raza, and Chakra P. Chaulagain from SUNY Upstate Medical University, University of Texas MD Anderson Cancer Center, Monmouth Medical Center, University of Balamand, Cleveland Clinic Ohio, UnityPoint Methodist, Houston Methodist Cancer Center, and Cleveland Clinic Florida report the literature on the latest treatment updates of Systemic Light chain (AL) amyloidosis and the ongoing clinical trials highlighting the future treatments. “In this manuscript, we discuss the general approach towards treating patients with amyloidosis and dive into the future perspectives in this multi-systemic disease.” Systemic AL amyloidosis is a monoclonal plasma cell proliferative disorder characterized by deposition of amyloidogenic monoclonal light chain fragments causing organ dysfunction. It is a fatal disease and if not diagnosed and treated early can lead to organ failure and potentially death. The renal system along with the cardiovascular system are the most common organs involved, but other organs such as the gut and liver can be involved as well. The initial evaluation of patients requires confirming the diagnosis with tissue biopsy and staining with Congo red followed by confirmatory typing with mass spectrometry of the Congo red positive tissue. Then establishing the extent of the organs involvement by various staging and biomarkers testing. The treatment options and the tolerability of therapy depend on the disease staging, frailty and co-morbidities. The autologous hematopoietic cell transplantation (HCT) after high dose melphalan therapy is an effective strategy which is usually done after initial bortezomib induction therapy. Unfortunately, most systemic AL amyloidosis patients are not candidates for HCT due to frailty, old age, multi-organ involvement, and renal or heart failure at the time of diagnosis. While it is widely accepted that the patients need to be treated until they achieve complete hematologic response, the maintenance therapy after HCT is not well established in AL amyloidosis. “The relationship between AL amyloidosis and MGUS is less clear, but some studies suggest that the risk of developing AL amyloidosis may be increased in patients with MGUS. It is important for patients with these conditions to undergo regular monitoring and evaluation for signs of AL amyloidosis, as early diagnosis and treatment can improve outcomes.” DOI - https://doi.org/10.18632/oncotarget.28415 Correspondence to - Chakra P. Chaulagain - chaulac@ccf.org Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28415 Keywords - amyloidosis, management About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
A new research paper was published in Oncotarget's Volume 14 on March 11, 2023, entitled, “Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss.” Homozygous deletion of methylthioadenosine phosphorylase (MTAP) upregulates de novo synthesis of purine (DNSP) and increases the proliferation of neoplastic cells. This increases the sensitivity of breast cancer cells to DNSP inhibitors such as methotrexate, L-alanosine and pemetrexed. In their recent study, Maroun Bou Zerdan, Prashanth Ashok Kumar, Elio Haroun, Nimisha Srivastava, Jeffrey Ross, and Abirami Sivapiragasam from SUNY Upstate Medical University and Foundation Medicine, Inc. analyzed 7,301 metastatic breast cancer (MBC) patients that underwent hybrid-capture based comprehensive genomic profiling (CGP). “We provide one of the first large analyses of the spectrum of GA [genomic alterations] occurring in MTAP deleted MBC with the hope that this would enable identifying potential therapeutic agents in the future.” Tumor mutational burden (TMB) was determined on up to 1.1 Mb of sequenced DNA and microsatellite instability (MSI) was determined on 114 loci. Tumor cell PD-L1 expression was determined by IHC (Dako 22C3). 208 (2.84%) of MBC featured MTAP loss. MTAP loss patients were younger (p = 0.002) and were more frequently ER− (30% vs. 50%; p < 0.0001), triple negative (TNBC) (47% vs. 27%; p < 0.0001) and less frequently HER2+ (2% vs. 8%; p = 0.0001) than MTAP intact MBC. Lobular histology and CDH1 mutations were more frequent in MTAP intact (14%) than MTAP loss MBC (p < 0.0001). CDKN2A (100%) and CDKN2B (97%) loss (9p21 co-deletion) were significantly associated with MTAP loss (p < 0.0001). Likely associated with the increased TNBC cases, BRCA1 mutation was also more frequent in MTAP loss MBC (10% vs. 4%; p < 0.0001). As for immune checkpoint inhibitors biomarkers, higher TMB >20 mut/Mb levels in the MTAP intact MBC (p < 0.0001) and higher PD-L1 low expression (1–49% TPS) in the MTAP loss MTAP (p = 0.002) were observed. “MTAP loss in MBC has distinct clinical features with genomic alterations (GA) affecting both targeted and immunotherapies. Further efforts are necessary to identify alternative means of targeting PRMT5 and MTA2 in MTAP-ve cancers to benefit from the high-MTA environment of MTAP-deficient cancers.” Read the full research paper: DOI: https://doi.org/10.18632/oncotarget.28376 Correspondence to: Abirami Sivapiragasam - sivapira@upstate.edu Keywords: breast cancer, metastatic, MTAP loss About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
Ran D. Anbar, MD, FAAP, is board certified in both pediatric pulmonology and general pediatrics, offering hypnosis and counseling services at Center Point Medicine in La Jolla (La HOY-A, I figured it out, thank you very much), California, and Syracuse, New York. Dr. Anbar is also a fellow and approved consultant of the American Society of Clinical Hypnosis. Dr. Anbar is a leader in clinical hypnosis, and his 20 years of experience have allowed him to successfully treat over 5,000 children. He also served as a professor of pediatrics and medicine and the director of pediatric pulmonology at SUNY Upstate Medical University in Syracuse, New York, for 21 years. Dr. Anbar also worked as a guest editor and advisory editor for the American Journal of Clinical Hypnosis. His experience has offered him the opportunity to direct and co-direct more than 20 clinic workshops on the subject of pediatric hypnosis. Additionally, he has trained more than a thousand healthcare providers and lectured all over the world. In addition to his teaching and lecturing experiences, Dr. Anbar has been the principal investigator in 10 published case studies of pediatric hypnosis and involved in research trials of children with cystic fibrosis and other pulmonary disorders. He is a published author of more than 50 articles, abstracts, and book chapters on pediatric functional disorders and pediatric hypnosis. Graduating from the University of California-San Diego with undergraduate degrees in biology and psychology, Dr. Anbar earned his medical degree from the University of Chicago Pritzker School of Medicine. He completed his pediatric residency and pediatric pulmonary fellowship training at the Massachusetts General Hospital and Harvard Medical School in Boston. Dr. Anbar received training in hypnosis from the Society of Developmental and Behavioral Pediatrics and the American Society of Clinical Hypnosis. In this episode, Dr. Anbar and I talk about what clinical hypnosis actually is compared to what you might see in popular culture, amazing stories of hypnosis in use, how trauma and hypnosis can intersect, and how it can be used for healing. For more information about Dr. Anbar, visit https://centerpointhypnosis.com/dr-anbar. Follow me @joshkorac on TikTok, Instagram, and YouTube for video clips, podcast previews, and more mental health content! If you are in a mental health crisis, please call 988 or go to your nearest emergency room. If you are from Colorado and are interested in scheduling a session, please reach out at sojourncounselingco.com/josh or josh@sojourncounselingco.com.
Dr. Lindsey Gurin is a clinical assistant professor of neurology, psychiatry, and rehabilitation medicine at NYU Langone Health. She is dual board-certified in neurology and psychiatry and currently serves as Director of Behavioral Neurology at NYU Langone Orthopedics Hospital, where she provides neuropsychiatric consultation to the Rusk acute inpatient brain injury rehabilitation service. She also is Director of the NYU Combined Psychiatry/Neurology Residency Training Program. Dr. Gurin has published on neuropsychiatric manifestations of brain injury and her current research interests include psychosis after brain injury; disorders of consciousness; and catatonia in patients with neurologic disorders. Dr. Brian Im is heavily involved in program development and academic medicine. He has an active role in brain injury rehabilitation research at NYU. After completing medical school at SUNY Upstate Medical University, a rehabilitation residency at NYU School of Medicine/Rusk Rehabilitation, and a fellowship in brain injury medicine at UMDNJ/Johnson Rehabilitation Institute, his subsequent tenure at Bellevue Hospital focused upon an interest in improving brain injury rehabilitation for underserved populations. He remains involved in this research at Bellevue Hospital while at his current role as the director for brain injury rehabilitation medicine at NYU/Rusk Rehabilitation. In Part One, the discussion included the following: a description of the care provided at NYU for patients who experience a brain injury from the perspective of the overall number and kinds of personnel involved and the clinical facilities in which they work; early neurorehabilitation and recovery from disorders of consciousness after severe COVID-19; and the kinds of challenges involved, such as arriving at a correct diagnosis of disorders of consciousness that could prove difficult because of a combination of patient and health system factors. In Part Two, the discussion included the following: long COVID with brain fog and treatments that are being tried; a definition of the terms catatonia and hypoxia-ischemia and a description of their causes; challenges involved in diagnosing and treating catatonia effectively in a timely manner; possible outcome of ineffective treatment occurring if catatonia is under-recognized diagnostically, and current and future research endeavors at NYU pertaining to brain injury.
Dr. Lindsey Gurin is a clinical assistant professor of neurology, psychiatry, and rehabilitation medicine at NYU Langone Health. She is dual board-certified in neurology and psychiatry and currently serves as Director of Behavioral Neurology at NYU Langone Orthopedics Hospital, where she provides neuropsychiatric consultation to the Rusk acute inpatient brain injury rehabilitation service. She also is Director of the NYU Combined Psychiatry/Neurology Residency Training Program. Dr. Gurin has published on neuropsychiatric manifestations of brain injury and her current research interests include psychosis after brain injury; disorders of consciousness; and catatonia in patients with neurologic disorders. Dr. Brian Im is heavily involved in program development and academic medicine. He has an active role in brain injury rehabilitation research at NYU. After completing medical school at SUNY Upstate Medical University, a rehabilitation residency at NYU School of Medicine/Rusk Rehabilitation, and a fellowship in brain injury medicine at UMDNJ/Johnson Rehabilitation Institute, his subsequent tenure at Bellevue Hospital focused upon an interest in improving brain injury rehabilitation for underserved populations. He remains involved in this research at Bellevue Hospital while at his current role as the director for brain injury rehabilitation medicine at NYU/Rusk Rehabilitation. In Part One, the discussion included the following: a description of the care provided at NYU for patients who experience a brain injury from the perspective of the overall number and kinds of personnel involved and the clinical facilities in which they work; early neurorehabilitation and recovery from disorders of consciousness after severe COVID-19; and the kinds of challenges involved, such as arriving at a correct diagnosis of disorders of consciousness that could prove difficult because of a combination of patient and health system factors. In Part Two, the discussion included the following: long COVID with brain fog and treatments that are being tried; a definition of the terms catatonia and hypoxia-ischemia and a description of their causes; challenges involved in diagnosing and treating catatonia effectively in a timely manner; possible outcome of ineffective treatment occurring if catatonia is under-recognized diagnostically, and current and future research endeavors at NYU pertaining to brain injury.
What did we learn about the relationship between PTSD and the gut microbiome this year? What are pherines? How can they reduce anxiety, according to research that was published this year? What other exciting news about psychopharmacology do you have to share with us? In this episode, Dr. Cutler addresses these questions and so much more about this past year in psychopharmacology. Dr. Andrew Cutler is the Chief Medical Officer (CEO) at the Neuroscience Education Institute (NEI). Dr. Cutler has deeply rooted knowledge in clinical experience, academic experience, and emerging science in psychiatry through clinical trials. He also worked closely with federal regulators and legislators to advocate for improved mental health care as part of the Clinton health care reform effort, leading to the Mental Health Parity Act of 1996. Among his notable leadership positions, Dr. Cutler is currently Clinical Associate Professor of Psychiatry, SUNY Upstate Medical University and previously served as Courtesy Assistant Professor of Psychiatry at University of Florida, and has been the principal investigator on more than 400 psychiatric and medical clinical trials. Dr. Cutler received a BS in biology from Haverford College in Philadelphia, and then received his medical degree from the University of Virginia School of Medicine, where he was elected to Alpha Omega Alpha honor medical society. He completed his medical internship, internal medicine residency, and psychiatry residency at the University of Virginia, where he served as Chief Resident of Psychiatric Medicine. Dr. Cutler then served as Assistant Professor and Director of Psychiatric Medicine at the University of Chicago. He is board certified in internal medicine and psychiatry.
In this episode of SurgOnc Today®, Mio Kitano, MD, MS, FACS, FSSO, Surgical Oncologist at UT Health San Antonio, TX, is joined by Mashaal Dhir, MD, FACS, FSSO, Surgical Oncologist and Section Chief of HPB Surgery at The SUNY Upstate Medical University in Syracuse, NY, and Nathan Bahary, MD, PhD, Division Chief of Medical Oncology at the Allegheny Health Network Cancer Institute and Director of AHNCI Clinical Research in Pittsburgh, PA. They discuss the most up-to-date information on how to diagnose and manage small bowel NET. Moderator: Mio Kitano, MD, MS, FACS, FSSO - UT Health San Antonio Faculty: Mashaal Dhir, MD, FACS, FSSO - SUNY Upstate Medical University Nathan Bahary, MD, PhD - Allegheny Health Network
On this episode of the Psychology Talk Podcast, Dr. Hoye is joined by Dr. Ran Ambar. Dr. Ran D. Anbar, is a board-certified pediatric pulmonologist and general pediatrician. He is a leader in field of clinical hypnosis, and has 20 years of experience treating children. He has also served as a professor of pediatrics and medicine and the director of pediatric pulmonology at SUNY Upstate Medical University in Syracuse, New York, for 21 years.Dr. Anbar also worked as a guest editor and advisory editor for the American Journal of Clinical Hypnosis. He has co-directed more than 20 clinic workshops on the subject of pediatric hypnosis. In addition to his teaching and lecturing experiences, Dr. Anbar has been the principal investigator in 10 published case studies of pediatric hypnosis and involved in research trials of children with cystic fibrosis and other pulmonary disorders. He is a published author of more than 50 articles, abstracts, and book chapters on pediatric functional disorders and pediatric hypnosis.Dr. Anbar discusses his new book, “Changing Children's Lives with Hypnosis: A Journey to the Center.” Dr. Anbar's Website:https://www.centerpointmedicine.com/provider/ran-d-anbar-md-faapDr. Anbar's Book:https://www.amazon.com/Changing-Childrens-Lives-Hypnosis-Journey/dp/1538153661The Psychology Talk Podcast is a unique conversation about psychology around the globe. Your host, clinical psychologist Dr. Scott Hoye discusses psychology with mental health practitioners and experts to keep you informed about issues and trends in the industry. They also tackle mental health trends and issues in their home: Chicago.https://psych-talk.comhttps://www.instagram.com/psychtalkpodcast/https://www.facebook.com/psychtalkpodcastDr. Hoye's Clinical Practice: https://chicagopsychservices.com
It's been more than four months since the Supreme Court ruled that there is no constitutional right to abortion in Dobbs v. Jackson Women's Health Organization. While the Dobbs decision has somewhat disappeared from the headlines, millions have had to live with its dangerous consequences. We talk with Dr. Carolyn Kay, obstetrician-gynecologist, to unpack what the last months have meant for people with uteruses, healthcare providers, and the country as a whole. Dr. Carolyn Kay is an obstetrician-gynecologist with a focus on cervical pre-cancer and cancer, racial disparities in cervical cancer screening, and the use of digital technology to address unmet needs in women's health. She is a contributor to the global movement to eliminate cervical cancer while working to move the needle on physician education and health literacy in historically excluded communities. She majored in mathematics and biology at Bryn Mawr College and earned her medical degree at the SUNY Upstate Medical University in New York. You can email us at podcast@womeninsciencepdx.org and follow us @women_in_science_pdx on Instagram, Twitter, and Facebook.
Tara puts three-and-a-half questions about love to Bob Lebel, a clinical geneticist in Syracuse, New York. Bob Lebel is a congenital Roman Catholic, came to ELCA as an adult. Married, three sons, four grandchildren. Earned advance degrees in Zoology, Theology, Ethics and Genetics; physician teaching and practicing medical genetics and genetic counseling at SUNY Upstate Medical University. He enjoys singing in church, gardening with his wife, reading classics, listening to “classical” music, going to plays/musicals, and writing (over 300 publications ranging from poems to book reviews to scientific research and a book on genetic counseling).Support the show
In this CME episode, Dr. Andrew Cutler interviews Dr. Vladimir Maletic about novel agents in development for Major Depressive Disorder or MDD. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-MDD. Learning Objectives: After completing this educational activity, you should be better able to: Describe novel mechanisms of action of agents under investigation for the treatment of depression Explain the potential implications of novel rapid-acting and multi-modal agents in optimizing outcomes for patients with unipolar depression Integrate newly available options for depression into clinical practice Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types. The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Assistant: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Mental Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any potential conflicts of interest were identified and mitigated prior to the activity being planned, developed, or presented. InterviewerAndrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva IntervieweeVladimir Maletic, MD, MS Clinical Professor of Psychiatry, University of South Carolina School of Medicine, Greenville, SC Consultant/Advisor: AbbVie, Alfasigma, Alkermes, Biogen/Sage, Intracellular, Ironshore, Janssen, Lundbeck, Otsuka, Relmada, Sunovion, Supernus, Takeda Speakers Bureau: AbbVie, Alfasigma, Alkermes, Biogen/Sage, Intracellular, Ironshore, Janssen, Lundbeck, Otsuka, Sunovion, Supernus, Takeda Pre-Interview AuthorSabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competency and strategies for understanding and reducing the impact of implicit bias can be found in this handout. Support: This activity is supported by an unrestricted educational grant from Sage Therapeutics, Inc. Released: September 26, 2022 CME/CE credit expires: September 26, 2025
In this episode, Dr. Andrew Cutler interviews Dr. Karl Doghramji on best practices for the treatment and management of insomnia. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-Sleep Learning Objectives: After completing this educational activity, you should be better able to: Utilize assessment tools in the diagnosis of insomnia Address challenges in the pharmacologic treatment of insomnia Implement evidence-based pharmacological treatments for insomnia Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types. The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Assistant: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content were required to disclose all relevant financial relationships. Any potential conflicts of interest were identified and mitigated prior to the activity being planned, developed, or presented. InterviewerAndrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NYChief Medical Officer, Neuroscience Education Institute, Carlsbad, CAConsultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris IntervieweeKarl Doghramji, MDProfessor, Department of Psychiatry & Human Behavior; Associate Professor, Departments of Neurology and of Medicine; Medical Director, Jefferson Sleep Disorders Center; Program Director, Fellowship in Sleep Medicine; Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PAResearch/Grant: Harmony, Inspire Consultant/Advisor: Axsome, Eisai, Jazz, Harmony, Idorsia, Imbrium, Inspire Stockholder: Merck Pre-Interview AuthorSabrina K. Bradbury-Segal, PhDMedical Writer, Neuroscience Education Institute, Carlsbad, CANo financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competency, and strategies for understanding and reducing implicit bias can be found in this handout. Support: This activity is supported by an unrestricted educational grant from Eisai. Released: August 31, 2022 CE credit expires: August 31, 2025
This interview is with Margaret Turk, MD, Vice-chairman of the PM&R Program at SUNY Upstate Medical University and Co-Editor-and-Chief of the Disability and Health Journal. She showcases the versatility of a career in PM&R. As a pediatric rehabilitation specialist and long-term advocate for people with disabilities, Dr. Turk shares her insights on key topics like integrating disability education into medical curriculum and how to be an advocate for our patients on an individual and national level. This podcast is brought to you by the AAP's Medical Student Council.
In today's CME episode, Dr. Andrew Cutler will be interviewing Dr. Leslie Citrome about the safety and efficacy of VMAT2 inhibitors for the treatment of tardive dyskinesia. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-TD03 Learning Objectives: After completing this educational activity, you should be better able to: Recognize the safety and efficacy of VMAT2 inhibitors for the treatment of tardive dyskinesia Individualize treatment regimens for patients with tardive dyskinesia, utilizing FDA-approved medications Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types. The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Assistant: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Mental Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. InterviewerAndrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva IntervieweeLeslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Eisai, Enteris BioPharma, HLS Therapeutics, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Merck, Neurocrine, Novartis, Noven, Otsuka, Ovid, Relmada, Reviva, Sage, Sunovion, Supernus, Teva, University of Arizona Speakers Bureau: AbbVie/Allergan, Acadia, Alkermes, Angelini, Eisai, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Pfizer, Reviva (options) Pre-Interview AuthorSabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competency and strategies for understanding and reducing the impact of implicit bias can be found in this handout. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences. Released: July 27, 2022 CME/CE credit expires: July 27, 2025
The Federal Trade Commission unanimously launched a formal inquiry into the business practices of the prescription drug middleman industry—known as pharmacy benefit managers (PBMs)—in early June 2022 due to the overwhelming response of more than 24,000 public comments during their request for information. Listen to ACCC's Matt Devino and Dr. Rahul Seth discuss why every voice is critical in grassroots advocacy efforts on both the federal and state level, and how cancer professionals who moonlight as patient advocates can help improve access to care and reduce financial toxicity for people living with cancer. Speakers Matt Devino, MPH Director, Cancer Care Delivery & Health Policy Association of Community Cancer Centers Rahul Seth, DO Assistant Professor of Medicine State University of New York Upstate Medical University Related Resources State by State: Advocacy Advances PBM Reform, Part 1 State by State: Advocacy Advances PBM Reform, Part 2 FTC Requests Public Comments on the Impact of Pharmacy Benefit Managers' Practices FTC Launches Inquiry Into Prescription Drug Middlemen Industry Oncology State Societies Advocacy Engagement Pilot ACCC Legislative Action Center
Staying physically active is not only important for people with osteoarthritis, but all adults. Participating in physical activity can help improve mobility, physical conditioning and reduce the risk of falls. However, despite the numerous health benefits of staying physically active, many older adults do not meet the recommended guidelines. We know it is often hard staying active so wanted to unpack that and give some tips and tricks for staying active. In this week's episode of Joint Action, we are joined by Mariana Wingood to discuss how we can increase our levels of physical activity. Mariana is a physiotherapist who received her Doctorate in Physical Therapy from SUNY Upstate Medical University in 2012. In 2014, she became a Certified Exercise Expert of Aging Adults, in 2015 a Geriatric Certified Specialist, and in 2021, she completed her PhD in Interprofessional Health Sciences and her Masters in Public Health. Mariana's research interests are related to physical activity and aging, with a focus on addressing physical activity prescription barriers identified by outpatient physical therapists treating individuals 50 years and older. RESOURCESJournal articles Physical Activity and Physical Activity Participation Barriers Among Adults 50 years and Older During the COVID-19 PandemicThe Inventory of Physical Activity Barriers for Adults 50 Years and Older: Refinement and Validation Community-Dwelling Older Adults and Physical Activity Recommendations: Patterns of Aerobic, Strengthening, and Balance Activities Feet/Footwear-Related Fall Risk Screening Tool for Older Adults: Development and Content Validation APTA Geriatrics' Guiding Principles for Best Practices in Geriatric Physical Therapy: An Executive Summary Pain Neuroscience Education for Older Adults WebsitesGo4LifeVivifrailNational Council on AgingCONNECT WITH MARIANATwitter @elevatingEBPCONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! See acast.com/privacy for privacy and opt-out information.
Kevin Antshel, PhD, is Professor of Psychology, Director of the Clinical Psychology doctoral program and Director of the ADHD Lifespan, Treatment Education and Research (ALTER) program at Syracuse University. He is also an Adjunct Associate Professor of Psychiatry at SUNY-Upstate Medical University in Syracuse, NY. His research interests focus on understanding the heterogeneity of ADHD, especially ADHD in the context of medical disorders such as 22q11.2 deletion syndrome and phenylketonuria. Clinically, Dr. Antshel has focused on developing and testing innovative psychosocial treatments for adolescents and young adults with ADHD and associated conditions. More recently, Dr. Antshel has focused on issues related to college students with ADHD including how best to reduce stimulant misuse on college campuses. Listen to this inspiring Parenting With Impact episode with Kevin Antshel about Stimulant misuse and management in college students. Stimulant use can be prevalent on campus for students who don't have a prescription, not understanding the risks. Here is what to expect on this week's show: Kevin's prevention and intervention education for college freshman The importance of parental monitoring of these medications at home- counting pills Understanding diversion- requests to buy your student's legitimate prescription Links Mentioned: Brooke Molina http://yfrp.pitt.edu/people/brooke-molina-phd https://chadd.org/ Connect with Kevin: http://thecollege.syr.edu/people/faculty/pages/psy/antshel-kevin.html https://alterlab.syr.edu/ LinkedIn https://www.linkedin.com/in/kevin-antshel-46407826/ Recommended Treatment for Children and Teens with ADHD Tip-Sheet So -- your child has ADHD. Want to get past the confusion and the stigma really fast? This FREE Guide explains, in the simplest terms possible: What is recommended treatment for children and teens Ten things to consider when trying to make a decision about medication Exactly what to look for in a behavior therapy training program. Short, sweet, and to the point -- don't spend hours on the internet scouring. ImpactParents gives you exactly what you need to know without wasting any time or effort. Learn more about your ad choices. Visit megaphone.fm/adchoices
In this episode, Dr. Andrew Cutler interviews Dr. Diana Perkins on best practices for shared decision making and patient education. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-TD02 Learning Objectives: After completing this educational activity, you should be better able to: Educate patients and family members with mood disorders and schizophrenia about the symptoms of tardive dyskinesia Address psychosocial and quality-of-life concerns related to tardive dyskinesia in patients with mood disorders and schizophrenia Include patients, caregivers, and family members in shared decision-making when applicable to optimize patient outcomes before and during of treatment of tardive dyskinesia Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types. The following are being offered for this activity: Nurse Practitioner (ANCC): contact hours Pharmacy (ACPE): knowledge-based contact hours Physician (ACCME): AMA PRA Category 1 Credits ™ Physician Assistant (AAPA): Category 1 CME credits Psychology (APA): CE credits Social Work (ASWB-ACE): ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and resolved prior to the activity being presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva Interviewee Diana Perkins, MD, MPH Professor, Department of Psychiatry; Medical Director, Outreach and Support Intervention Services; University of North Carolina School of Medicine, Chapel Hill, NC Consultant/Advisor: Alkermes, Karuna Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies, and strategies for understanding and reducing implicit bias can be found in this can be found in this linked handout. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences. Released: May 27, 2022 CE credit expires: May 27, 2025
Thanks for tuning in to the Pharmacy Inspection Podcast! Today we have Pharmacist Greg Stanley on the show and we're going to be talking about implementation of an IV workflow system! Greg Stanley received his Bachelor of Science in Pharmacy degree in 1998, having also completed undergraduate research fellowships in Biological/Environmental Sciences and Polymer Sciences. He has over twenty-five years of experience with compounded sterile products; both in hospital and home infusion settings. Greg has extensive experience with policy development, staff training, pharmacy management and regulatory compliance. Currently, Greg is an Associate Director at SUNY Upstate Medical University. He is involved with several projects related to USP and USP . His oversight includes sterile compounding, hazardous compounding, and robotic/automated technologies.
I had the pleasure of interviewing Dr. Ran Anbar for this podcast about his new book entitled Changing Children's Lives with Hypnosis: A Journey to the Center. Dr. Ran, a board certified in both pediatric pulmonology and general pediatrics, offers hypnosis and counseling services at Center Point Medicine in La Jolla, California, and Syracuse, New York. Dr. Anbar is also a fellow and approved consultant of the American Society of Clinical Hypnosis. With his experience, he has successfully treat over 5,000 children. He also served as a professor of pediatrics and medicine and the director of pediatric pulmonology at SUNY Upstate Medical University in Syracuse, New York, for 21 years.
Ran D. Anbar, MD, FAAP, is board certified in both pediatric pulmonology and general pediatrics, offering hypnosis and counseling services at Center Point Medicine in La Jolla, California, and Syracuse, New York. Dr. Anbar is also a past president, fellow and approved consultant of the American Society of Clinical Hypnosis. Dr. Anbar is a leader in clinical hypnosis, and his 25 years of experience have allowed him to successfully treat over 7,000 children. He also served as a professor of pediatrics and medicine and the director of pediatric pulmonology at SUNY Upstate Medical University in Syracuse, New York, for 21 years. Dr. Anbar also worked as a guest editor and advisory editor for the American Journal of Clinical Hypnosis. His experience has offered him the opportunity to direct and co-direct more than 20 clinical workshops on the subject of pediatric hypnosis. Additionally, he has trained more than a thousand healthcare providers and lectured all over the world. https://youtu.be/r7POj8eTkoA In addition to his teaching and lecturing experiences, Dr. Anbar has been the principal investigator in 10 published case studies of pediatric hypnosis and involved in research trials of children with cystic fibrosis and other pulmonary disorders. He is a published author of more than 50 articles, abstracts, and book chapters on pediatric functional disorders and pediatric hypnosis. Graduating from the University of California-San Diego with undergraduate degrees in biology and psychology, Dr. Anbar earned his medical degree from the University of Chicago Pritzker School of Medicine. He completed his pediatric residency and pediatric pulmonary fellowship training at the Massachusetts General Hospital and Harvard Medical School in Boston. Dr. Anbar received training in hypnosis from the Society of Developmental and Behavioral Pediatrics and the American Society of Clinical Hypnosis.
© 2020-2025 Ivy Podcast Discovery LLC
